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Expression profiling has produced gene signatures 
prognostic for outcome in a number of cancers, with 
breast cancer heading the list in terms of numbers of 
studies and progress towards clinical use. Some of 
these signatures, which contain multiple genes, have 
been validated in several independent clinical series 
and have been approved for the clinic. Their usefulness 
lies not only in their ability to predict if a patient will 
die early or late or hopefully not at all, but also to spare 
patients from toxic treatment, e.g. chemotherapy, if it 
will not benefit them. The search for prognostic factors 
therefore represents more than just an academic 
exercise. Equally valuable would be to predict which 
treatment would the most effective against the tumor. 
In this issue of Oncotarget, Higgins and colleagues 
[1] describe another prognostic gene signature for 
breast cancer, this one being particularly unusual in 
containing just a single gene, POLQ (official name: 
polymerase DNA directed theta). Their stimulus to 
study this gene came from a recently published paper 
from their lab in which POLQ emerged from siRNA 
screening for genes determining radiosensitivity [2]. 
The exact role of this gene is still not entirely clear, 
although it has been reported to function in pathways 
dealing with DNA lesions, including base excision 
repair and translesional synthesis, consistent with a role 
in sensitivity to ionizing radiation. 
Given this finding, they naturally wanted to know if 
it had any clinical relevance, hence their study of 
several clinical series in which they or others had 
measured global gene expression using microarray 
technology. Breast cancers were an obvious choice 
given the amount of publically available expression 
data. Gratifyingly, POLQ turned out to be a strong 
prognostic marker in all but one of the series they 
studied, and even in this series it showed a strong 
trend. Several other gene signatures have been 
discovered and validated to have prognostic 
significance for breast cancer, so is POLQ better or 
different? They report that POLQ appears in some of 
the published signatures but not in others. By looking 
at genes co-regulated with POLQ, they also showed 
that many of the molecular pathways represented by 
these genes also occurred in the published signatures. 
Given the large difference in outcome found between 
high and low POLQ expressing tumors, the authors 
speculate that POLQ may be one of the most important 
driver genes in other signatures which contain POLQ. 
Further, they found that cyclin E (CCNE2), amazingly, 
was the only common gene between all three of the 
main published prognostic breast cancer signatures and 
the set of genes positively correlating with POLQ 
expression. Pursuing this, they could show that CCNE2 
was also prognostic by itself, independently of POLQ, 
and that the two genes together (POLQ and CCNE2) 
had even stronger prognostic power. 
While this is highly interesting and potentially 
useful, it would be even more useful to know why 
POLQ is prognostic, since only then can rationally 
chosen targeted interventions be employed for patients 
with high POLQ expressing tumors. So does POLQ 
simply monitor radiosensitivity, which would then 
suggest the use of a radiosensitizer strategy? This is 
probably unlikely since some patients in their series 
(around 17%) did not receive radiotherapy, while all 
received surgery, and the majority received 
chemotherapy and hormone therapy. Given the 
magnitude of the POLQ effect, it is more likely, as 
speculated by the authors, that this gene provides a 
measure of general malignancy, related to high 
proliferation status, defective p53 signaling, high tumor 
grade and negative ER status. Endpoints used in the 
clinical studies also included metastases, and so it is 
possible that POLQ could also be correlated with 
invasive and other properties of tumor cells rendering 
them more capable of metastasizing. This reasoning 
also applies to CCNE2. All this needs further study, 
including a breakdown of the data into different 
endpoints and the different treatments. 
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On a practical note, the finding that one or two 
genes have such strong prognostic value suggests the 
use of robust and routine assays such as 
immunochemistry or PCR-based methods which can be 
carried out rapidly in the majority of centers. Such 
methods should also facilitate further validation on 
independent patient series. Finally, given these 
interesting findings, one of the next questions is 
whether  POLQ and/or CCNE2 also have prognostic 
significance in other cancers. I expect we will hear 
about this in the near future and we await such results 
with interest. 
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